No significantly increased risks observed for autoimmune disorder, atopic or allergic disorder, neurodevelopmental disorder
By Elana Gotkine HealthDay Reporter
TUESDAY, July 15, 2025 (HealthDay News) — Early childhood exposure to aluminum-adsorbed vaccines is not associated with an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders, according to a study published online July 15 in the Annals of Internal Medicine.
Niklas Worm Andersson, M.D., Ph.D., from Statens Serum Institut in Copenhagen, Denmark, and colleagues examined the association between cumulative aluminum exposure from early childhood vaccination and the risk for autoimmune, atopic or allergic, and neurodevelopmental disorders in Denmark from 1997 to 2020. Participants included 1,224,176 children born in Denmark between 1997 and 2018 who were alive and resided in the country at age 2 years.
The researchers observed no association for cumulative aluminum exposure from vaccination during the first two years of life with increased rates of any of the 50 chronic disorders assessed. Per 1-mg increase in aluminum exposure, adjusted hazard ratios were 0.98 (95 percent confidence interval, 0.94 to 1.02) for any autoimmune disorder, 0.99 (95 percent confidence interval, 0.98 to 1.01) for any atopic or allergic disorder, and 0.93 (95 percent confidence interval, 0.90 to 0.97) for any neurodevelopmental disorder. The upper bounds of the 95 percent confidence intervals were incompatible with relative increases greater than 10 or 30 percent for most individually analyzed outcomes.
“Findings were incompatible with moderate-to-large relative increases in the risks for autoimmune, atopic or allergic, and neurodevelopmental disorders associated with early childhood exposure to aluminum-adsorbed vaccines for most outcomes, although small relative increases could not be statistically excluded, particularly for some rarer outcomes,” the authors write.
Copyright © 2025 HealthDay. All rights reserved.
